Hydroxyzinum Hasco

Hydroxyzine hydrochloride, the active ingredient in Hydroxyzinum Hasco, is an antihistamine presented as a tablet for oral use. It treats allergic dermatitis, pruritus, anxiety, provides sedation before surgery, and helps control nausea and vomiting.

GNH USA supplies Hydroxyzinum Hasco as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydroxyzine hydrochloride is used to manage conditions related to histamine‑mediated reactions and anxiety.

Allergic dermatitis: reduces itching and inflammation associated with allergic skin reactions. Pruritus: relieves intense itching of various origins. Anxiety: provides short‑term anxiolytic effect in acute stress situations. Sedation before surgery: produces calming sedation for pre‑operative preparation. Nausea and vomiting: helps control postoperative or chemotherapy‑induced nausea and vomiting.

Hydroxyzine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Blurred vision - Constipation - Headache - Dizziness

Serious or Rare Side Effects: - Cardiac arrhythmia - Severe hypotension - Seizures - Anaphylactic or severe allergic reactions - Hepatic dysfunction - Blood dyscrasias such as agranulocytosis

Before prescribing hydroxyzine, clinicians should consider several safety aspects.

Pregnancy: Category B1 – use only if the potential benefit justifies the potential risk to the fetus. Driving: May cause drowsiness; advise patients to avoid operating machinery. Concomitant CNS depressants: Increased risk of profound sedation. Elderly: Heightened sensitivity; start at the lowest effective dose. Renal/hepatic impairment: Dose adjustment may be required. Store at below 25°C: keep in the original pack, protect from moisture.

Hydroxyzine can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: enhanced sedation and respiratory depression. - CNS depressants (benzodiazepines, barbiturates): risk of profound sedation. - Anticholinergic drugs: increased anticholinergic burden. - QT‑prolonging agents: potential for cardiac arrhythmia.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise hydroxyzine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Antihypertensives: possible additive hypotensive effect. - Other anticholinergic agents: may worsen dry mouth and constipation. - MAO inhibitors: potential for additive central effects.